Krzysztof Nieznanski

Dr. Krzysztof Nieznanski

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2017 in Protein Science
Verified
Journal Article
Closed access
PDF file
BNBartosz Nizynski
Bartosz Nizynski
WDWojciech Dzwolak
Wojciech Dzwolak
KNKrzysztof Nieznanski
Krzysztof Nieznanski

13 January 2012 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
TWTomasz Michał Wasiak
Tomasz Michał Wasiak
Maksim IonovMaksim Ionov
Maksim Ionov
KNKrzysztof Nieznanski
Krzysztof Nieznanski
HNHanna Nieznanska
Hanna Nieznanska
Oxana KlementievaOxana Klementieva
Oxana Klementieva
BKBarbara Klajnert-Maculewicz
Barbara Klajnert-Maculewicz

1 September 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KNKrzysztof Nieznanski
Krzysztof Nieznanski
JCJin-Kyu Choi
Jin-Kyu Choi
SCShugui Chen
Shugui Chen
KSKrystyna Surewicz
Krystyna Surewicz
WSWitold K. Surewicz
Witold K. Surewicz
The pathogenesis of Alzheimer disease appears to be strongly linked to the aggregation of amyloid-β (Aβ) peptide and, especially, formation of soluble Aβ1–42 oligomers. It was recently demonstrated that the cellular prion protein, PrPC, binds with high affinity to these oligomers, acting as a putative receptor that mediates at least some of their neurotoxic effects. Here we show that the soluble (i.e. glycophosphatidylinositol anchor-free) prion protein and its N-terminal fragment have a strong effect on the aggregation pathway of Aβ1–42, inhibiting its assembly into amyloid fibrils. Furthermore, the prion protein prevents formation of spherical oligomers that normally occur during Aβ fibrillogenesis, acting as a potent inhibitor of Aβ1–42 toxicity as assessed in experiments with neuronal cell culture. These findings may provide a molecular level foundation to explain the reported protective action of the physiologically released N-terminal N1 fragment of PrPC against Aβ neurotoxicity. They also suggest a novel approach to pharmacological intervention in Alzheimer disease.

1 August 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KNKrzysztof Nieznanski
Krzysztof Nieznanski
HNHanna Nieznanska
Hanna Nieznanska
KSKrzysztof Skowronek
Krzysztof Skowronek
KOKatarzyna M. Osiecka
Katarzyna M. Osiecka
DSDariusz Stępkowski
Dariusz Stępkowski

1 July 2016 in Neurobiology of Disease
Verified
Journal Article
Closed access
JSJonah J. Scott-McKean
Jonah J. Scott-McKean
KSKrystyna Surewicz
Krystyna Surewicz
JCJin-Kyu Choi
Jin-Kyu Choi
VRVernon A. Ruffin
Vernon A. Ruffin
ASAhlam I. Salameh
Ahlam I. Salameh
WSWitold K. Surewicz
Witold K. Surewicz

1 September 2020 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Open access
YKYevheniia Kravenska
Yevheniia Kravenska
HNHanna Nieznanska
Hanna Nieznanska
KNKrzysztof Nieznanski
Krzysztof Nieznanski
ELElena Lukyanetz
Elena Lukyanetz
Adam SzewczykAdam Szewczyk
Adam Szewczyk
PKPiotr Koprowski
Piotr Koprowski
A causative agent of Alzheimer's disease (AD) is a short amphipathic peptide called amyloid beta (Aβ). Aβ monomers undergo structural changes leading to their oligomerization or fibrillization. The monomers as well as all aggregated forms of Aβ, i.e., oligomers, and fibrils, can bind to biological membranes, thereby modulating membrane mechanical properties. It is also known that some isoforms of the large-conductance calcium-activated potassium (BKCa) channel, including the mitochondrial BKCa (mitoBKCa) channel, respond to mechanical changes in the membrane. Here, using the patch-clamp technique, we investigated the impact of full-length Aβ (Aβ1-42) and its fragment, Aβ25-35, on the activity of mitoBKCa channels. We found that all forms of Aβ inhibited the activity of the mitoBKCa channel in a concentration-dependent manner. Since monomers, oligomers, and fibrils of Aβ exhibit different molecular characteristics and structures, we hypothesized that the inhibition was not due to direct peptide-protein interactions but rather to membrane-binding of the Aβ peptides. Our findings supported this hypothesis by showing that Aβ peptides block mitoBKCa channels irrespective of the side of the membrane to which they are applied. In addition, we found that the enantiomeric peptide, D-Aβ1-42, demonstrated similar inhibitory activity towards mitoBKCa channels. As a result, we proposed a general model in which all Aβ forms i.e., monomers, oligomers, and amyloid fibrils, contribute to the progression of AD by exerting a modulatory effect on mechanosensitive membrane components.